2nd Biologics Manufacturing Japan 2021

Home to the second-largest pharmaceutical market in the world, Japan has poised itself as one of the most lucrative biotech hubs in Asia, and worldwide. Over recent years, the Japanese biologics market has opened its doors to both foreign companies entering the Japanese market and companies investing abroad. Japan’s biopharma sector has had a keen eye on alliance opportunities in markets beyond its borders and although the nature of its sector is a cautious one, its move towards transparency and international collaboration provides bountiful opportunities that both the domestic and international players stand to benefit from.

The 2nd edition of the Biologics Manufacturing Japan 2021, aims to provide a neutral platform to address the challenges faced in this sector including high costs incurred in the downstream purification of highly complex molecules, purification process development to maximize process economy, difficulties in process development, scale-up and technology transfer for biologics, reduction of Cost-of-Goods for large-scale manufacturing, insights into the regulatory perspective on common pitfalls in analytical and CMC studies, Single-Use Systems in USP & DSP and Cost-Benefit analysis of CMO outsourcing strategies.

Join the conference to interact with key and upcoming entities from Japanese Biologics space include Chugai Pharmaceutical, Kyowa Hakko Kirin, UMN Pharma, Daiichi Sankyo, Daiichi Sankyo, Asahi Glass Co., Astellas Pharma and Fujifilm Holdings Corp among others.